(BWAY) BrainsWay Ltd. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BWAY) BrainsWay Ltd. Complete Analysis Pack
Explore the Complete Growth Strategy Behind the Preview
This BrainsWay Ltd. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to help you assess strategic priorities and investment angles; the page shows a genuine preview/sample of the analysis so you can inspect format and insight before buying. Purchase the full version to get the complete, ready-to-use company-specific Ansoff Matrix report.
Market Penetration
US psychiatry-center adoption of dTMS
BrainsWay’s U.S. market penetration is about getting more use from existing psychiatry sites, not changing the device. In clinics already treating 6 relevant disorders—MDD, anxious depression, OCD, PTSD, bipolar disorder, and smoking addiction—every added patient per site lifts dTMS utilization and revenue. This is the cheapest Ansoff move because the platform is already cleared and sold in the United States.
Hospital account expansion in existing geographies
BrainsWay Ltd. can deepen penetration by adding psychiatry, neurology, and other departments in existing U.S., European, and Israeli hospital systems, using the same installed platform and clinical workflow. This keeps selling costs low and expands use inside accounts already trained on the system. The lever is more sites per health system, not new geographies.
Condition-breadth selling within one platform
BrainsWay’s dTMS platform can be sold across several conditions, so one installed system can serve depression, OCD, and smoking cessation, while clinical work extends into PTSD and schizophrenia. That broad indication mix lifts chair utilization and spreads revenue across more patient pools. It also lowers reliance on any single diagnosis, which makes the model less exposed to reimbursement or demand shifts.
Medical-professional referral growth
BrainsWay Ltd.’s medical-professional referral growth depends on turning more clinicians into active referrers for existing treatment centers. That lifts treatment volume inside the current footprint, so market penetration can rise without opening new sites. In Ansoff terms, this is deeper use of the current market, not geographic expansion.
- More clinician awareness
- More referrals to existing centers
- Higher utilization, no new geography
For BrainsWay Ltd., this can improve revenue per installed center and support steadier demand.
Installed-base utilization in current sites
BrainsWay Ltd. can lift revenue from its installed base by pushing higher patient throughput, broader indication use, and tighter clinic scheduling at sites already running dTMS. This is the cleanest market-penetration lever because it adds sales without adding new system installs. Every extra treatment slot at an active site improves yield from the current base.
- More visits per site
- More indications treated
- Higher chair-time density
- No new install needed
BrainsWay’s Cheapest Growth Move: More Revenue From the Same Centers
BrainsWay Ltd.’s market penetration case is simple: grow use inside the current installed base, not into new markets. One dTMS system can treat 6 disorders already, so more referrals, more visits, and tighter scheduling lift revenue per center without new installs.
| Lever | Data point | Penetration effect |
|---|---|---|
| Indications | 6 | More patient pools per site |
| Platform | 1 dTMS system | Higher chair-time use |
| Site focus | Existing centers | Lower selling cost |
This makes market penetration the cheapest Ansoff move for BrainsWay Ltd. because it adds volume from the same footprint, same workflow, and same cleared device.
What is included in the product
Detailed Word Document
Provides a clear Ansoff Matrix framework for analyzing BrainsWay Ltd.’s growth strategy across products and markets
Editable Excel File
Helps BrainsWay Ltd. quickly map growth options and remove expansion uncertainty with a clear Ansoff snapshot.
Reference Sources
Provides a concise, traceable bibliography of primary sources to validate BrainsWay Ltd. growth paths in Ansoff Matrix analysis.
Market Development
Broader European rollout
BrainsWay already sells dTMS in Europe, so this is market development, not a new product launch. The next step is to enter more of the 27 European Union healthcare systems and nearby markets with the same device, which widens reach without changing the core platform. If reimbursement and clinic adoption scale, each new country can add incremental recurring treatment demand.
Deeper international expansion outside the US and Europe
BrainsWay’s deeper push into countries beyond the US, Europe, and Israel is pure market development: the dTMS therapy stays the same, only the addressable market changes. That fits non-invasive neurostimulation demand in new health systems, where adoption can scale without new clinical positioning. In 2025, the key upside is more installed-use potential from the same cleared platform.
Israel-wide institutional reach
BrainsWay is headquartered in Jerusalem, and Israel-wide institutional reach fits a market-development move: expand the same Deep TMS platform from a few reference centers into more hospitals and medical centers across the country. That broadens the customer base without changing the core product, lowering rollout friction and lifting utilization across an existing local market. The upside is more clinic accounts, more treated patients, and stronger national visibility for the platform.
Neurology and rehabilitation clinic entry
BrainsWay’s deep TMS can move from psychiatry into neurology and rehab clinics, because it already fits conditions like Parkinson’s, multiple sclerosis, Alzheimer’s, and post-stroke recovery. This is a new market for the same product: the World Health Organization says over 55 million people live with dementia, and stroke affects about 15 million people each year.
- New buyers: neurology and rehab centers
- Same device, new care setting
- Targets stroke, MS, Parkinson’s, Alzheimer’s
Non-psychiatric care pathways
BrainsWay Ltd. can use non-psychiatric care pathways to reach pain clinics and neurorehab units without changing the Deep TMS platform. That matters because its cleared use base already spans more than psychiatry, including chronic pain and neurologic recovery settings. One device, more buying centers.
- Expands demand beyond mental-health-only sites
- Targets chronic pain and rehab budgets
- Keeps sales tied to the same platform
BrainsWay Expands Deep TMS Reach Across Europe and New Care Settings
BrainsWay Ltd.’s market development is widening Deep TMS use into more countries and care settings without changing the device. The same platform can reach more of the 27 EU health systems and add neurology, rehab, and pain clinics, where WHO says dementia affects 55 million people and stroke hits 15 million yearly. More sites mean more patient volume from one cleared product.
| Move | Data |
|---|---|
| EU reach | 27 systems |
| Dementia | 55M people |
| Stroke | 15M cases/yr |
Preview the Actual Deliverable
BrainsWay Ltd. Reference Sources
This is the actual BrainsWay Ltd. Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality, structured growth options, and clear strategic recommendations tailored to the company.
Product Development
New indication protocols on dTMS
BrainsWay Ltd. can use product development by adding new dTMS protocols to its installed base, so the same clinics treat more conditions. By 2025, the platform already supported FDA-cleared use in major areas like OCD and smoking cessation, and each added indication can lift device utilization without needing new hardware.
That matters because protocol expansion turns one system into a broader clinical menu, which can deepen recurring treatment volume and support higher revenue per site.
Neurological-use protocols for existing sites
BrainsWay Ltd.’s neurological-use protocols for Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson’s disease are product development, not market entry, because they are new protocols sold through existing hospital and medical-center ties. That matters in a market where one added protocol can expand use without rebuilding distribution.
The logic is clear: same sites, new clinical use cases.
For BrainsWay Ltd., this can lift revenue per account and deepen site penetration while keeping selling costs tied to an installed base rather than new customer acquisition.
Specialized treatment settings and accessories
BrainsWay can add site-level workflow tools and treatment accessories to its neurostimulation platform to deepen use at existing clinics and hospitals, which is classic product development. This fits the company’s installed base first, so adoption can rise without a new geography push. In FY2025/FY2026, tie this to utilization, repeat sessions, and lower setup time.
That matters because BrainsWay’s core growth engine is already tied to provider adoption, so accessories that make treatment easier can lift seat usage and stickiness. A single software or hardware add-on can expand value per site faster than opening new markets. If each center treats more patients per day, revenue can scale with little extra sales cost.
Platform generation upgrades
BrainsWay’s platform generation upgrades are a product move in an existing market: it can refresh dTMS hardware and software without changing its core therapy category. In 2025, that fits a company still scaling recurring use across psychiatry and neurology sites, where better usability can lift adoption and treatment flow.
Existing customers should see faster setup, simpler session management, and easier workflow control, which can support retention and upgrades. This matters because BrainsWay’s model depends on installed systems and repeat clinical use, not a new market entry.
- Same dTMS category
- Better clinic usability
- Stronger treatment management
- Upgrade-driven growth
Broader multi-condition treatment offering
BrainsWay’s Deep TMS already spans 4 FDA-cleared indications, including major depressive disorder, OCD, smoking addiction, and anxious depression. Packaging these uses into one platform lets current clinics standardize on one device, one training path, and one service contract. That is classic product development: more value from the same installed base.
The move also raises wallet share because a clinic treating 2 or more conditions can keep patients inside the BrainsWay system instead of buying separate tools.
- 4 cleared uses, one platform
- Higher standardization for clinics
- More reasons to stay with BrainsWay
BrainsWay Grows by Adding More Uses to the Same Clinics
Product development for BrainsWay Ltd. means adding new Deep TMS protocols and workflow upgrades for the same clinic base. In FY2025, the platform already had 4 FDA-cleared uses, so each new protocol can raise utilization and revenue per site without new hardware. Same customers, more clinical uses.
| Metric | FY2025 |
|---|---|
| FDA-cleared uses | 4 |
| Growth lever | New protocols |
| Revenue effect | Higher site use |
Diversification
Psychiatry-to-neurology revenue shift
BrainsWay already serves both mental health and neurological use cases, so psychiatry-to-neurology diversification can build a second revenue engine instead of leaning mainly on depression demand. Its global reach across 60+ countries gives it a ready channel to sell rehabilitation and neurology systems faster. That shift can reduce concentration risk and widen the addressable market beyond psychiatry alone.
Chronic-pain care expansion
Chronic pain is already in BrainsWay Ltd.’s condition set, so packaging it as a separate line widens demand beyond psychiatric clinics. In the U.S., chronic pain affects about 51 million adults, so the buyer pool is much broader than office-based psychiatry. That shift can pull sales into hospitals, integrated delivery networks, and pain centers, cutting end-market concentration risk.
Neurodegenerative-disease positioning
BrainsWay’s mention of Alzheimer’s disease and Parkinson’s disease widens its scope beyond depression into longer-care neurology, where WHO says about 55 million people live with dementia and 8.5 million with Parkinson’s globally. That shifts the sales story from acute psychiatry clinics to chronic disease pathways. It also gives BrainsWay a broader TAM than its core depression use case.
Rehabilitation-market participation
BrainsWay’s move into rehabilitation-market participation can diversify demand beyond outpatient psychiatry, since post-stroke recovery and multiple sclerosis care sit in a different treatment channel. Stroke affects about 12.2 million people each year worldwide, and more than 2.8 million people live with MS globally, so rehab demand is large and recurring. Its non-invasive Deep TMS platform gives Company Name a practical base to reach rehab-focused clinics and hospitals.
- Different buyer set: rehab clinics and hospitals
- Large need: stroke and MS patient pools
- Lower reliance on psychiatry reimbursement cycles
- Uses existing non-invasive neurostimulation know-how
Multi-vertical neuromodulation platform
BrainsWay Ltd. uses one Deep TMS base across mental health, neurology, pain, and rehab, so diversification is real business logic, not just a label. Its multi-indication portfolio already spans major depressive disorder, OCD, and smoking cessation, which reduces reliance on any single disease pool and supports cross-vertical sales from one installed platform.
- One technology base
- Multiple therapy verticals
- Lower disease-area dependence
- Stronger cross-sell potential
BrainsWay Expands Deep TMS Into Pain and Neurology Markets
BrainsWay Ltd.’s diversification builds on one Deep TMS platform across psychiatry, neurology, pain, and rehab. That lowers reliance on depression alone and opens larger care pools, including 51 million U.S. adults with chronic pain, 55 million people with dementia, and 8.5 million with Parkinson’s globally.
| Area | Key data |
|---|---|
| Pain | 51M U.S. adults |
| Neurology | 55M dementia, 8.5M Parkinson’s |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.